DXCM Quote, Financials, Valuation and Earnings

iRhythm Technologies has a net margin of 10.17% compared to DexCom's net margin of -19.35%. DexCom's return on equity of 24.26% beat iRhythm Technologies's return on equity of -112.03%.

DexCom has a consensus price target of $98.59, signalling upside risk potential of 17.95%. On the other hand iRhythm Technologies has an analysts' consensus of $145.92 which suggests that it could fall by -0.02%. Given that DexCom has higher upside potential than iRhythm Technologies, analysts believe DexCom is more attractive than iRhythm Technologies.

DexCom has a beta of 1.443, which suggesting that the stock is 44.319% more volatile than S&P 500. In comparison iRhythm Technologies has a beta of 1.413, suggesting its more volatile than the S&P 500 by 41.267%.

DexCom has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iRhythm Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DexCom pays -- of its earnings as a dividend. iRhythm Technologies pays out -- of its earnings as a dividend.

DexCom quarterly revenues are $1B, which are larger than iRhythm Technologies quarterly revenues of $158.7M. DexCom's net income of $105.4M is higher than iRhythm Technologies's net income of -$30.7M. Notably, DexCom's price-to-earnings ratio is 62.37x while iRhythm Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DexCom is 8.27x versus 7.39x for iRhythm Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Masimo has a net margin of 10.17% compared to DexCom's net margin of -45.89%. DexCom's return on equity of 24.26% beat Masimo's return on equity of -39.91%.

DexCom has a consensus price target of $98.59, signalling upside risk potential of 17.95%. On the other hand Masimo has an analysts' consensus of $183.74 which suggests that it could grow by 8.72%. Given that DexCom has higher upside potential than Masimo, analysts believe DexCom is more attractive than Masimo.

DexCom has a beta of 1.443, which suggesting that the stock is 44.319% more volatile than S&P 500. In comparison Masimo has a beta of 1.187, suggesting its more volatile than the S&P 500 by 18.716%.

DexCom has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Masimo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DexCom pays -- of its earnings as a dividend. Masimo pays out -- of its earnings as a dividend.

DexCom quarterly revenues are $1B, which are larger than Masimo quarterly revenues of $372M. DexCom's net income of $105.4M is higher than Masimo's net income of -$170.7M. Notably, DexCom's price-to-earnings ratio is 62.37x while Masimo's PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DexCom is 8.27x versus 4.65x for Masimo. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of 10.17% compared to DexCom's net margin of 6.22%. DexCom's return on equity of 24.26% beat Insulet's return on equity of 36.9%.

DexCom has a consensus price target of $98.59, signalling upside risk potential of 17.95%. On the other hand Insulet has an analysts' consensus of $336.01 which suggests that it could grow by 12.01%. Given that DexCom has higher upside potential than Insulet, analysts believe DexCom is more attractive than Insulet.

DexCom has a beta of 1.443, which suggesting that the stock is 44.319% more volatile than S&P 500. In comparison Insulet has a beta of 1.346, suggesting its more volatile than the S&P 500 by 34.619%.

DexCom has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DexCom pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

DexCom quarterly revenues are $1B, which are larger than Insulet quarterly revenues of $569M. DexCom's net income of $105.4M is higher than Insulet's net income of $35.4M. Notably, DexCom's price-to-earnings ratio is 62.37x while Insulet's PE ratio is 53.96x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DexCom is 8.27x versus 10.09x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

Tandem Diabetes Care has a net margin of 10.17% compared to DexCom's net margin of -55.69%. DexCom's return on equity of 24.26% beat Tandem Diabetes Care's return on equity of -81.14%.

DexCom has a consensus price target of $98.59, signalling upside risk potential of 17.95%. On the other hand Tandem Diabetes Care has an analysts' consensus of $32.70 which suggests that it could grow by 89.68%. Given that Tandem Diabetes Care has higher upside potential than DexCom, analysts believe Tandem Diabetes Care is more attractive than DexCom.

DexCom has a beta of 1.443, which suggesting that the stock is 44.319% more volatile than S&P 500. In comparison Tandem Diabetes Care has a beta of 1.478, suggesting its more volatile than the S&P 500 by 47.763%.

DexCom has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tandem Diabetes Care offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DexCom pays -- of its earnings as a dividend. Tandem Diabetes Care pays out -- of its earnings as a dividend.

DexCom quarterly revenues are $1B, which are larger than Tandem Diabetes Care quarterly revenues of $234.4M. DexCom's net income of $105.4M is higher than Tandem Diabetes Care's net income of -$130.6M. Notably, DexCom's price-to-earnings ratio is 62.37x while Tandem Diabetes Care's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DexCom is 8.27x versus 1.15x for Tandem Diabetes Care. Usually stocks with elevated PS ratios are considered overvalued.